Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride
Patients resuscitated with 4% Albumin will have less incidence and reduced severity of pressure injuries than patients resuscitated with 0.9% Sodium Chloride due to the improved intravascular oncotic pressure effected from higher albumin levels.
Pressure Ulcer, Area
Pressure Ulcer, Grade
Length of ICU Stay
Drug: 4% Albumin / 0.9% Sodium Chloride
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Diagnostic
|Official Title:||The Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride Administration (Substudy of SAFE Protocol 153711)|
- Patients receiving 4% Albumin will have less incidence and reduced severity of pressure injuries.
- Is there a difference in the incidence of pressure injuries between those patients resuscitated with 4% Albumin and patients resuscitated with 0.9% Sodium Chloride
- Is there a difference in the severity of pressure injuries between those patients resuscitated with 4% Albumin and patients resuscitated with 0.9% Sodium Chloride.
|Study Start Date:||July 2002|
|Study Completion Date:||August 2003|
|Primary Completion Date:||August 2003 (Final data collection date for primary outcome measure)|
Pressure ulcers incur multiple risks to the patient. The disruption of the skin is a portal of entry for infection , which may remain localised to the site or become blood borne. A pressure ulcer can lead to protein and fluid losses from the wound exudate. Many authors have theorised the existence of a relationship between the development of pressure ulcers and low serum albumin levels however, there is no strong evidence to prove this correlation. The literature does demonstrate a clear relationship between people with existing pressure ulcers and the presence of low serum albumins. Specifically serum albumin levels <30mg/dl have been associated with the incidence of pressure ulcer development.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00228657
|The Alfred Hospital, Prahran,|
|Melbourne, Victoria, Australia, 3181|
|Principal Investigator:||Shena M Graham, BN||The Alfred Hospital, Prahran, Melbourne, Australia|